vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
Elanco Animal Health Inc is the larger business by last-quarter revenue ($1.1B vs $1.1B, roughly 1.0× PERRIGO Co plc). Elanco Animal Health Inc runs the higher net margin — -24.1% vs -127.8%, a 103.7% gap on every dollar of revenue. On growth, Elanco Animal Health Inc posted the faster year-over-year revenue change (12.2% vs -2.5%). PERRIGO Co plc produced more free cash flow last quarter ($148.6M vs $46.0M). Over the past eight quarters, PERRIGO Co plc's revenue compounded faster (1.3% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
ELAN vs PRGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.1B |
| Net Profit | $-276.0M | $-1.4B |
| Gross Margin | 51.5% | 32.6% |
| Operating Margin | -22.6% | -116.0% |
| Net Margin | -24.1% | -127.8% |
| Revenue YoY | 12.2% | -2.5% |
| Net Profit YoY | -3350.0% | -3093.9% |
| EPS (diluted) | $-0.55 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $1.1B | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $1.2B | $1.1B | ||
| Q1 25 | $1.2B | $1.0B | ||
| Q4 24 | $1.0B | $1.1B | ||
| Q3 24 | $1.0B | $1.1B | ||
| Q2 24 | $1.2B | $1.1B | ||
| Q1 24 | $1.2B | $1.1B |
| Q4 25 | $-276.0M | $-1.4B | ||
| Q3 25 | $-34.0M | $7.5M | ||
| Q2 25 | $11.0M | $-8.4M | ||
| Q1 25 | $67.0M | $-6.4M | ||
| Q4 24 | $-8.0M | $-44.4M | ||
| Q3 24 | $364.0M | $-21.0M | ||
| Q2 24 | $-50.0M | $-108.4M | ||
| Q1 24 | $32.0M | $2.0M |
| Q4 25 | 51.5% | 32.6% | ||
| Q3 25 | 53.4% | 36.1% | ||
| Q2 25 | 57.5% | 34.4% | ||
| Q1 25 | 57.3% | 37.6% | ||
| Q4 24 | 50.9% | 33.9% | ||
| Q3 24 | 52.2% | 37.2% | ||
| Q2 24 | 58.2% | 37.0% | ||
| Q1 24 | 57.3% | 33.1% |
| Q4 25 | -22.6% | -116.0% | ||
| Q3 25 | -4.4% | 7.0% | ||
| Q2 25 | 2.0% | 4.3% | ||
| Q1 25 | 5.0% | 4.5% | ||
| Q4 24 | -5.0% | 10.0% | ||
| Q3 24 | 54.3% | 7.4% | ||
| Q2 24 | -2.7% | -2.5% | ||
| Q1 24 | 1.0% | -5.1% |
| Q4 25 | -24.1% | -127.8% | ||
| Q3 25 | -3.0% | 0.7% | ||
| Q2 25 | 0.9% | -0.8% | ||
| Q1 25 | 5.6% | -0.6% | ||
| Q4 24 | -0.8% | -3.9% | ||
| Q3 24 | 35.3% | -1.9% | ||
| Q2 24 | -4.2% | -10.2% | ||
| Q1 24 | 2.7% | 0.2% |
| Q4 25 | $-0.55 | $-10.23 | ||
| Q3 25 | $-0.07 | $0.05 | ||
| Q2 25 | $0.02 | $-0.06 | ||
| Q1 25 | $0.13 | $-0.05 | ||
| Q4 24 | $-0.01 | $-0.32 | ||
| Q3 24 | $0.73 | $-0.15 | ||
| Q2 24 | $-0.10 | $-0.79 | ||
| Q1 24 | $0.06 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | — |
| Total DebtLower is stronger | $3.9B | — |
| Stockholders' EquityBook value | $6.5B | $2.9B |
| Total Assets | $13.4B | $8.5B |
| Debt / EquityLower = less leverage | 0.60× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | — | ||
| Q3 25 | $505.0M | $432.1M | ||
| Q2 25 | $539.0M | $454.2M | ||
| Q1 25 | $487.0M | $409.9M | ||
| Q4 24 | $468.0M | $558.8M | ||
| Q3 24 | $490.0M | $1.5B | ||
| Q2 24 | $416.0M | $542.8M | ||
| Q1 24 | $345.0M | $658.5M |
| Q4 25 | $3.9B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $4.3B | — | ||
| Q3 24 | $4.4B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.8B | — |
| Q4 25 | $6.5B | $2.9B | ||
| Q3 25 | $6.7B | $4.4B | ||
| Q2 25 | $6.8B | $4.5B | ||
| Q1 25 | $6.4B | $4.4B | ||
| Q4 24 | $6.1B | $4.3B | ||
| Q3 24 | $6.5B | $4.6B | ||
| Q2 24 | $5.9B | $4.5B | ||
| Q1 24 | $6.1B | $4.7B |
| Q4 25 | $13.4B | $8.5B | ||
| Q3 25 | $13.6B | $10.1B | ||
| Q2 25 | $13.7B | $10.1B | ||
| Q1 25 | $12.9B | $9.8B | ||
| Q4 24 | $12.6B | $9.6B | ||
| Q3 24 | $13.3B | $11.2B | ||
| Q2 24 | $13.8B | $10.4B | ||
| Q1 24 | $14.0B | $10.6B |
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.96× | — | ||
| Q1 24 | 0.95× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $175.4M |
| Free Cash FlowOCF − Capex | $46.0M | $148.6M |
| FCF MarginFCF / Revenue | 4.0% | 13.4% |
| Capex IntensityCapex / Revenue | 5.4% | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $175.4M | ||
| Q3 25 | $219.0M | $51.7M | ||
| Q2 25 | $237.0M | $75.9M | ||
| Q1 25 | $-4.0M | $-64.5M | ||
| Q4 24 | $177.0M | $312.6M | ||
| Q3 24 | $162.0M | $42.2M | ||
| Q2 24 | $200.0M | $9.5M | ||
| Q1 24 | $2.0M | $-1.4M |
| Q4 25 | $46.0M | $148.6M | ||
| Q3 25 | $127.0M | $29.8M | ||
| Q2 25 | $180.0M | $56.7M | ||
| Q1 25 | $-69.0M | $-90.0M | ||
| Q4 24 | $130.0M | $274.9M | ||
| Q3 24 | $120.0M | $15.1M | ||
| Q2 24 | $166.0M | $-18.9M | ||
| Q1 24 | $-22.0M | $-26.5M |
| Q4 25 | 4.0% | 13.4% | ||
| Q3 25 | 11.2% | 2.9% | ||
| Q2 25 | 14.5% | 5.4% | ||
| Q1 25 | -5.8% | -8.6% | ||
| Q4 24 | 12.7% | 24.2% | ||
| Q3 24 | 11.7% | 1.4% | ||
| Q2 24 | 14.0% | -1.8% | ||
| Q1 24 | -1.8% | -2.4% |
| Q4 25 | 5.4% | 2.4% | ||
| Q3 25 | 8.1% | 2.1% | ||
| Q2 25 | 4.6% | 1.8% | ||
| Q1 25 | 5.4% | 2.4% | ||
| Q4 24 | 4.6% | 3.3% | ||
| Q3 24 | 4.1% | 2.5% | ||
| Q2 24 | 2.9% | 2.7% | ||
| Q1 24 | 2.0% | 2.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 6.89× | ||
| Q2 25 | 21.55× | — | ||
| Q1 25 | -0.06× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.06× | -0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
